S-EPMC10477319 - Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia. - OmicsDI

Unknown

Dataset Information

Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.

ABSTRACT:

SUBMITTER: Awada H

PROVIDER: S-EPMC10477319 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature